Sight for Sore Eyes: New Eye Drops Approved
BromSite (bromfenac) approved to treat inflammation, prevent pain for cataract surgery patients
The US Food and Drug Administration (FDA) has approved eye drops for patients undergoing cataract surgery.
The FDA recently approved BromSite (bromfenac) to prevent pain and treat inflammation in the eye for patients undergoing cataract surgery. BromSite is actually the first nonsteroidal anti-inflammatory drug (NSAID) approved specifically for patients undergoing cataract surgery.
NSAIDs work to decrease inflammation and pain because they stop the release of certain natural substances that cause pain and swelling.
In clinical trials, more patients who were given BromSite did not have pain the day after cataract surgery when compared to those patients who were given a placebo. Furthermore, more patients who were given BromSite did not have inflammation 15 days after cataract surgery when compared to those patients given a placebo.
Sun Ophthalmics' BromSite is expected to launch in the United States in the second half of 2016.
All information on this site is provided “as-is” for informational purposes only and is not a substitute for medical advice or treatment. You should consult with a medical professional if you have any questions about your health.
More health news
Prescription DrugsBausch + Lomb Receives FDA Approval for PROLENSA
Prolensa approved to treat postoperative inflammation in patients
Health NewsFDA Approves First Implantable Miniature Telescope to Improve Sight of AMD patients
Device designed to help those with end-stage, age-related macular degeneration
Health NewsSeeing Cataracts Clearly
Cataract Awareness Month highlights surgery as successful treatment option